THE COUNCIL OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Economic Community,

Having regard to Council Directive 85/511/EEC of 18 November 1985 introducing Community measures for the control of foot-and-mouth disease ( 1 ), as amended by Decision 90/423/EEC ( 2 ), and in particular Article 14 thereof,

Having regard to the proposal from the Commission,

Whereas by 1 January 1992 all Member States must have discontinued routine vaccination against foot-and-mouth disease in their territory;

Whereas, however, in view of the high density of susceptible species in some parts of the Community, it is necessary to provide for the possibility of emergency vaccination in a limited area, in circumstances where slaughter of the entire herd may not be sufficient to eliminate the virus;

Whereas Community reserves of foot-and-mouth disease vaccine should be established, based on stocks of concentrated inactivated antigen capable of being quickly converted into vaccine for emergency use;

Whereas the antigen should be stored at four separate locations; whereas facilities for formulation, bottling and distribution must also be provided;

Whereas the criteria for the supply and storage of antigen and its conversion into vaccine should be established;

Whereas the national institutes responsible for maintaining the reserve of antigen should cooperate with the Community Coordinating Institute for foot-and-mouth disease vaccines designated by Decision 91/665/EEC ( 3 ) in order to ensure the potency, safety and stability of the antigen, and vaccines produced therefrom, and to ensure that the quantity and sub-types kept are appropriate to the risk, on the basis, in particular, of information supplied by the reference laboratory for the identification of foot-and-mouth disease virus designated by Decision 89/531/EEC ( 4 );

Whereas Article 14 of Council Decision 90/424/EEC of 26 June 1990 on expenditure in the veterinary field ( 5 ), as amended by Decision 91/133/EEC ( 6 ), provides that the establishment of a Community reserve of foot-and-mouth disease vaccines may be eligible for Community aid,

HAS ADOPTED THIS DECISION:

— the supply of concentrated inactivated antigen by establishments designated by Member States,

— the storage, in reserves, of the antigen referred to in the first indent,

— the guarantee of rapid formulation, bottling and distribution by establishments designated by Member States.

1. antigen banks: appropriate premises, such as those designated in Article 3 (1), for the storage of Community reserves of concentrated inactivated antigen for the production of foot-and-mouth disease vaccine;

2. Community Coordinating Institute for foot-and-mouth disease vaccine (CCI): the institute designated by Decision 91/665/EEC.

— the Laboratoire de pathologie bovine du centre national d'études vétérinaires et alimentaires, Lyon (France),

— the Istituto Zooprofilatico Sperimentale di Brescia (Italy),

— any other establishment designated in accordance with the procedure laid down in Article 10.

(a) to store the Community reserves of concentrated inactivated foot-and-mouth disease virus antigens in such a way as to maintain their usefulness for the production of a safe and potent vaccine for emergency use against foot-and-mouth disease, including the keeping of adequate records of the conditions under which the antigen is stored;

(b) to liaise with the CCI for the purposes of:

(c) to deliver concentrated inactivated antigen to establishments designated for the formulation, bottling and distribution of the vaccine, at the request of the Commission or a Member State under the conditions provided for in the second and third subparagraphs of Article 13 (3) of Directive 85/511/EEC, for use in the Member State or third country in which the vaccine is to be used.

(a) the technical requirements concerning the supply of antigens, in accordance with Annex II;

(b) the supply and delivery of the specified quantity to the antigen bank in a form suitable for long-term storage in liquid nitrogen, or other storage methods recognized, under the procedure laid down in Article 10 after obtaining the opinion of the Scientific Veterinary Committee, as giving at least equivalent stability, including the provision of separate replicates suitable for routine testing;

(c) a guarantee that any antigen supplied will meet the safety and stability requirements defined for vaccine by the European Pharmacopoeia, as well as the required potency (6 PD 50/dose) when tested as specified for vaccine;

(d) the reagents and materials to be used in the formulation of the vaccine;

(e) a guarantee that the vaccine supplied complies fully with the European Pharmacopoeia;

(f) supply of the vaccine, within a given time and at a guaranteed rate of delivery, in bottles of suitable size, labelled in the language or languages of the country in which the vaccine is to be used;

(g) compliance by the establishment which supplies an antigen with the ‘minimum standards for laboratories working with foot-and-mouth disease virus in vitro and in vivo’ — European Commission for the control of foot-and-mouth disease — 26th session, Rome, April 1985, on the basis, where necessary, of a report by experts acting under the procedure laid down in Article 10;

(h) quoted costs for the supply of the antigen or the provision of the service, as appropriate.

— the distribution of antigen reserves between antigen banks,

— general procedures for replacing antigen reserves,

— the rules to be followed, should Decision 90/424/EEC be invoked, in making available to third countries vaccines produced from antigens to be replaced in accordance with the second indent,

— any derogations, after obtaining the opinion of the Standing Veterinary Committee, from the figure of 6 PD 50/dose laid down in Article 5 (2) (c) for new vaccines.